Phase II Study of a PARP Inhibitor, Talazoparib, in HER2- Metastatic Breast Cancer (MBC) with a Somatic BRCA1/2mutation Identified in a Cell-Free DNA or Tumor Tissue Genotyping Assay.
Journal of Clinical Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined